InvestorsHub Logo
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

Re: runncoach post# 6232

Monday, 05/14/2018 3:41:15 PM

Monday, May 14, 2018 3:41:15 PM

Post# of 21540
The other risk in waiting for non-memantine results is missing a possible deal with a large biotech, either for a region (Japan?) or for a distinct indication (MS?).

If a deal contains significant upfront cash (> $50M) and large milestones, then cash is no longer a concern and several new trials can be started.

I could see the share price easily doubling with a partnership that brings in significant cash.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News